奥曲肽治疗恶性肠梗阻早期炎症的临床疗效及安全性评价  

Clinical efficacy and safety of octreotide in the treatment of early postoperative inflammation of malignant bowel obstruction

作　　者：梁启新[1] 汪晓明[1] 于庆生[1] 

机构地区：[1]安徽中医药大学第一附属医院普外科,合肥230011

出　　处：《中国临床药理学杂志》2016年第7期603-605,共3页The Chinese Journal of Clinical Pharmacology

基　　金：2010年度安徽中医学院临床科学研究基金资助项目(2010LC-022A)

摘　　要：目的观察奥曲肽治疗恶性肠梗阻术后早期炎症的临床疗效及安全性。方法将68例术后早期炎性肠梗阻患者随机分为对照组34例和试验组34例。对照组第1周给予静脉注射地塞米松5 mg,q8 h,1周后逐渐停药;试验组在对照组的基础上,给予皮下注射奥曲肽注射液0.1 mg,q8 h,直至胃肠排气、排便等功能恢复正常或中转手术治疗才予以停药。比较2组患者的临床疗效、体征改善时间、辅助检查的改善情况,以及不良反应发生率。结果治疗后,试验组的总有效率94.12%显著高于对照组64.71%(P<0.05)。治疗后,试验组的腹胀、腹痛、恶心、呕吐及肛门排气排便等临床症状体征改善时间均明显短于对照组(P<0.05)。治疗后,2组患者的胃肠减压量和C反应蛋白均较治疗前降低,且试验组的降低程度明显优于对照组,同时试验组纠正水电解质及酸碱失衡时间及X线片检查示恢复正常时间均明显低于对照组(P<0.05)。2组患者治疗过程中未发现严重的不良反应。结论奥曲肽治疗恶性肠梗阻术后早期炎症的临床疗效确切,无明显不良反应。Objective To evaluate the clinical efficacy and safety of octreotide in the treatment of early postoperative inflammation of malignant bowel obstruction with. Methods Sixty- eight patients with early postoperative inflammation of malignant bowel obstruction were randomly divided into control group（ n = 34） and treatment group（ n = 34）. Control group was received dexamethasone 5 mg intravenously,q8 h,gradual withdrawal after 1 week. Treatment group was treated with octreotide 0. 1mg subcutaneous injection q8 h on the basic treatment of control group,until the gastrointestinal exhaust,defecation and other functions returned to normal or transit surgery only to be discontinued. The clinical efficacy,signs of improvement time,situation of laboratory examinations and incidence of adverse drug reactions were compared between two groups.Results After treatment,total effective rate in treatment group was higher than that of control group（ 94. 12% vs 64. 71%,P〈0. 05）.After treatment,the improvement time of clinical symptoms and signs for bloating,abdominal pain, nausea, vomiting and defecation flatus in treatment group was shorter than that of control group（ P〈0. 05）. After treatment,the two groups of decompression volume and C- reactiveprotein were lower than those before treatment（ P〈0. 05）,and degree drop of treatment group was better than that in control group（ P〈0. 05）. The time of correcting water and electrolyte and acid- base balance and X- ray examination showed normal time in treatment group were lower than that in control group（ P〈0. 05）. There were no collected serious adverse drug reactions in two groups during the treatment. Conclusion Octreotide has a definitive clinical efficacy for the treatment of early postoperative inflammation of malignant bowel obstruction,and has no significant adverse drug reactions.

关 键 词：奥曲肽 恶性肠梗阻 早期炎症 临床疗效 安全性 

分 类 号：R975[医药卫生—药品]